Longeveron Inc. (NASDAQ:LGVN – Get Rating) Director Rock Soffer sold 8,000 shares of the stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $7.78, for a total value of $62,240.00. Following the completion of the transaction, the director now directly owns 676,351 shares of the company’s stock, valued at approximately $5,262,010.78. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Rock Soffer also recently made the following trade(s):
- On Friday, May 20th, Rock Soffer sold 7,500 shares of Longeveron stock. The stock was sold at an average price of $8.06, for a total value of $60,450.00.
LGVN stock traded down $0.36 on Tuesday, reaching $7.52. 122,901 shares of the company traded hands, compared to its average volume of 3,652,006. Longeveron Inc. has a one year low of $2.84 and a one year high of $45.00. The company has a market cap of $157.26 million, a P/E ratio of -8.41 and a beta of -2.05. The firm has a fifty day simple moving average of $9.15 and a 200-day simple moving average of $10.50.
Separately, Maxim Group began coverage on Longeveron in a research report on Thursday, March 24th. They issued a “buy” rating and a $14.00 target price for the company.
A number of hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada purchased a new position in Longeveron during the second quarter valued at $28,000. UBS Group AG lifted its position in Longeveron by 272.9% during the third quarter. UBS Group AG now owns 9,633 shares of the company’s stock valued at $34,000 after purchasing an additional 7,050 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Longeveron during the fourth quarter valued at $122,000. Virtu Financial LLC purchased a new position in Longeveron during the fourth quarter valued at $137,000. Finally, TownSquare Capital LLC purchased a new position in Longeveron during the third quarter valued at $51,000. 2.20% of the stock is owned by institutional investors.
About Longeveron (Get Rating)
Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.
- Get a free copy of the StockNews.com research report on Longeveron (LGVN)
- Zoom Video Communications Is Primed To Launch Higher
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.